Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Matthew Rice

Gastroenterology New Orleans, LA Medical Doctor

NPI 1235313982 CMS profile 740409

1514 Jefferson Highway, New Orleans, LA 70121

Open in the dashboard

General payments

$1,337

12 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Matthew Rice of New Orleans, LA is reported in the CMS Open Payments database as having received $1,337 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $219 2
2023 General $465 4
2022 General $246 2
2021 General $72 1
2019 General $336 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Rice
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Matthew Rice were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Matthew Rice Gastroenterology median Middle half National median
2019 $336 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $72 $352 $106–$1,054 $132
2022 $246 $448 $129–$1,270 $149
2023 $465 $533 $150–$1,390 $160
2024 $219 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic, Inc. $321 3 payments
  2. ERBE USA Inc $270 2 payments
  3. Boston Scientific Corporation $256 3 payments
  4. Allergan Inc. $250 2 payments
  5. Genzyme Corporation $131 1 payment
  6. FUJIFILM Medical Systems USA, Inc. $108 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,337 12 payments
Products named General payments · program years 2019–2024
  1. GI Genius $184 2 payments
  2. Erbe VIO3 Endoscopy $150 1 payment
  3. Barrx $138 1 payment
  4. DUPIXENT $131 1 payment
  5. LINZESS $125 1 payment
  6. VIBERZI $125 1 payment
  7. ZENPEP $125 1 payment
  8. Erbe VIO3 Gastroenterology $120 1 payment
  9. FUJIFILM $108 1 payment
  10. RESOLUTION CLIP $86 1 payment
  11. Other $72 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

621

Median for Gastroenterology: 569

Drug cost

$107,813

Median for Gastroenterology: $104,976

Branded share of claims

49.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $59,514
Linzess Linaclotide Brand 35 $33,903
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 80 $5,581
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 119 $2,343
Omeprazole Generic 114 $1,878
Pantoprazole Sodium Generic 117 $1,527
Esomeprazole Magnesium Generic 20 $746
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 35 $563
Sucralfate Generic 11 $489
Dicyclomine Hcl Generic 24 $443

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$44,694

Medicare's payments for the services billed

Medicare patients

244

Average age 72

Services billed

396

143 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 43%
Diabetes 39%
Ischemic heart disease 35%
Heart failure 34%
Atrial fibrillation 32%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record